BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 32896960)

  • 1. Real-world outcomes for neoadjuvant capecitabine versus infusional 5-fluorouracil in the treatment of locally advanced rectal cancer.
    Loft M; Wong HL; Kosmider S; Lee M; Tie J; Wong R; Jones IT; Croxford M; Steel M; Faragher I; Guerrieri M; Christie M; Gibbs P
    Intern Med J; 2021 Aug; 51(8):1262-1268. PubMed ID: 32896960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing pathological complete response rate using oral capecitabine versus infusional 5-fluorouracil with preoperative radiotherapy in rectal cancer treatment.
    Jootun N; Evans T; Mak J; Makin G; Platell C
    ANZ J Surg; 2018 Jan; 88(1-2):62-65. PubMed ID: 28982208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of capecitabine in locally advanced rectal cancer treatment: an update.
    Fernández-Martos C; Nogué M; Cejas P; Moreno-García V; Machancoses AH; Feliu J
    Drugs; 2012 May; 72(8):1057-73. PubMed ID: 22621694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial.
    Allegra CJ; Yothers G; O'Connell MJ; Beart RW; Wozniak TF; Pitot HC; Shields AF; Landry JC; Ryan DP; Arora A; Evans LS; Bahary N; Soori G; Eakle JF; Robertson JM; Moore DF; Mullane MR; Marchello BT; Ward PJ; Sharif S; Roh MS; Wolmark N
    J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26374429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
    Eisterer W; Piringer G; DE Vries A; Öfner D; Greil R; Tschmelitsch J; Samonigg H; Sölkner L; Gnant M; Thaler J;
    Anticancer Res; 2017 May; 37(5):2683-2691. PubMed ID: 28476845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Capecitabine vs continuous infusion 5-FU in neoadjuvant treatment of rectal cancer. A retrospective review.
    Saif MW; Hashmi S; Zelterman D; Almhanna K; Kim R
    Int J Colorectal Dis; 2008 Feb; 23(2):139-45. PubMed ID: 17909820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capecitabine versus 5-fluorouracil in neoadjuvant chemoradiotherapy of locally advanced rectal cancer: A meta-analysis.
    Zhu J; Zeng W; Ge L; Yang X; Wang Q; Wang H
    Medicine (Baltimore); 2019 Apr; 98(17):e15241. PubMed ID: 31027072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.
    Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J;
    BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative long-course chemoradiation for localized rectal cancer: A retrospective comparison of response and outcome between 5-fluorouracil/leucovorin versus capecitabine.
    Kunheri B; Gurram B; Madhavan R; Makuny D
    Indian J Cancer; 2016; 53(4):518-523. PubMed ID: 28485342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal cancer: a meta analysis.
    An X; Lin X; Wang FH; Goodman K; Cai PQ; Kong LH; Fang YJ; Gao YH; Lin JZ; Wan DS; Pan ZZ; Ding PR
    Eur J Cancer; 2013 Mar; 49(4):843-51. PubMed ID: 23063351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been?
    Glynne-Jones R; Dunst J; Sebag-Montefiore D
    Ann Oncol; 2006 Mar; 17(3):361-71. PubMed ID: 16500912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of postoperative chemotherapy among older patients with non-metastatic rectal cancer treated with preoperative chemoradiotherapy.
    Lund JL; Sturmer T; Sanoff HK
    J Geriatr Oncol; 2016 May; 7(3):176-86. PubMed ID: 26926829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative Radiochemotherapy in Rectal Cancer: Is There an Impact of Oxaliplatin on Pathologic Complete Response and Survival Rates under "Real World" Conditions?
    Grabenbauer A; Aigner T; Göbel H; Leibl BJ; Lamberti C; Grabenbauer GG; Distel LV
    Cells; 2023 Jan; 12(3):. PubMed ID: 36766741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative chemoradiotherapy for rectal cancer: a comparison between intravenous 5-fluorouracil and oral capecitabine.
    Ramani VS; Sun Myint A; Montazeri A; Wong H
    Colorectal Dis; 2010 Aug; 12 Suppl 2():37-46. PubMed ID: 20618366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized controlled pilot study to compare capecitabine-oxaliplatin with 5-FU-leucovorin as neoadjuvant concurrent chemoradiation in locally advanced adenocarcinoma of rectum.
    Saha A; Ghosh SK; Roy C; Saha ML; Choudhury KB; Chatterjee K
    J Cancer Res Ther; 2015; 11(1):88-93. PubMed ID: 25879343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective Comparison of mFOLFOXIRI With XELOX/SOX as Neoadjuvant Chemotherapy for Locally Advanced Rectal Cancer.
    Kodama H; Terazawa T; Ishizuka Y; Yukami H; Aoki M; Miyamoto T; Yamaguchi T; Shimamoto F; Kii T; Goto M; Hamamoto H; Osumi W; Yamamoto M; Tanaka K; Okuda J; Uchiyama K; Higuchi K
    In Vivo; 2021; 35(2):977-985. PubMed ID: 33622892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive Significance of Mucinous Histology on Pathologic Complete Response Rate Following Capecitabine-Based Neoadjuvant Chemoradiation in Rectal Cancer: a Comparative Study.
    Hosseini S; Nguyen N; Mohammadianpanah M; Mirzaei S; Bananzadeh AM
    J Gastrointest Cancer; 2019 Dec; 50(4):716-722. PubMed ID: 29984382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial.
    Uehara K; Hiramatsu K; Maeda A; Sakamoto E; Inoue M; Kobayashi S; Tojima Y; Yoshioka Y; Nakayama G; Yatsuya H; Ohmiya N; Goto H; Nagino M
    Jpn J Clin Oncol; 2013 Oct; 43(10):964-71. PubMed ID: 23935207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
    Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
    [No Abstract]   [Full Text] [Related]  

  • 20. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.